{"id":56299,"date":"2023-04-27T16:06:30","date_gmt":"2023-04-27T14:06:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/brenus-pharma-unveils-groundbreaking-preclinical-results-for-stc-10101-a-promising-new-drug-candidate-targeting-colorectal-cancer-solid-tumors\/"},"modified":"2023-04-27T16:06:30","modified_gmt":"2023-04-27T14:06:30","slug":"brenus-pharma-unveils-groundbreaking-preclinical-results-for-stc-10101-a-promising-new-drug-candidate-targeting-colorectal-cancer-solid-tumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/brenus-pharma-unveils-groundbreaking-preclinical-results-for-stc-10101-a-promising-new-drug-candidate-targeting-colorectal-cancer-solid-tumors\/","title":{"rendered":"Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors"},"content":{"rendered":"
\n

\nAt the Annual Conference of the American Association for Cancer Research<\/a><\/i><\/span> (AACR), <\/i>in Orlando (Florida) from April 14th<\/sup> to 19th<\/sup><\/i><\/p>\n

LYON, France–(BUSINESS WIRE)–#AACR23<\/a>–Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (Stimulated Tumor-Cells) Technology Platform.<\/a><\/p>\n

<\/a><\/p>\n

\nInnovative models for anti-tumor vaccine development were highlighted: Inovotion<\/a>\u2019s CAM (chorioallantoic model) in-ovo assay <\/i>and Explicyte<\/a>\u2019s ex-vivo co-cultured assay, were used to characterize the mechanism of action through a specific immune response, and validate the anti-tumor effects of STC-1010.<\/b><\/p>\n

\nThese models comply with the FDA\u2019s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer<\/b>.<\/p>\n

\nThe first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay. Results obtained in-ovo<\/i> confirmed the anti-tumor efficacy <\/b>-mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models<\/b>. Dendritic cells primed by STC-1010<\/b> will induce a multi specific pool of T-lymphocytes against the tumor without toxicity.<\/b><\/p>\n

\nThe second study evaluated the functional activity of STC-1010-primed dendritic cells (DCs) from PBMCs human donors\u2019 isolation, to activate autologous CD8+ T cells and promote tumor cell death. The study evaluated the cross-priming and specificity of the immune response induced by STC-1010. Results showed that STC-1010 is an efficient strategy to educate the immune system by cross-priming DCs and increasing the activity of specific CD8+ T cells (TCR sequencing) all of which promotes the significant tumor killing observed ex-vivo.<\/i><\/b><\/p>\n

\nTaken together, these studies provide promising results for the development of the STC-1010 and prove its potential to be presented into clinical setting for the treatment of patients with CRC.<\/p>\n

\nInnovative in vivo <\/i>model for anti-tumor vaccine development: Safety validation and preliminary efficacy evaluation of a new antitumor vaccine STC-1010 on human colorectal adenocarcinoma using the chicken CAM assay.<\/strong><\/p>\n

\nSession Title: Clinical Research Excluding Trials – Vaccines<\/strong><\/p>\n

\nAbstract Presentation Number: 6791<\/strong><\/p>\n